HK1199840A1 - 降伊波加因碱鹽非溶劑化物 - Google Patents

降伊波加因碱鹽非溶劑化物

Info

Publication number
HK1199840A1
HK1199840A1 HK15100394.5A HK15100394A HK1199840A1 HK 1199840 A1 HK1199840 A1 HK 1199840A1 HK 15100394 A HK15100394 A HK 15100394A HK 1199840 A1 HK1199840 A1 HK 1199840A1
Authority
HK
Hong Kong
Prior art keywords
ansolvates
noribogaine salt
noribogaine
salt ansolvates
salt
Prior art date
Application number
HK15100394.5A
Other languages
English (en)
Inventor
Richard D Gless
William C Schinzer
Original Assignee
Demerx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47881233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199840(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Demerx Inc filed Critical Demerx Inc
Publication of HK1199840A1 publication Critical patent/HK1199840A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15100394.5A 2011-09-15 2015-01-14 降伊波加因碱鹽非溶劑化物 HK1199840A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535300P 2011-09-15 2011-09-15
PCT/US2012/055597 WO2013040471A2 (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates

Publications (1)

Publication Number Publication Date
HK1199840A1 true HK1199840A1 (zh) 2015-07-24

Family

ID=47881233

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100394.5A HK1199840A1 (zh) 2011-09-15 2015-01-14 降伊波加因碱鹽非溶劑化物

Country Status (18)

Country Link
US (4) US9040520B2 (zh)
EP (1) EP2755658A4 (zh)
KR (2) KR20140062472A (zh)
CN (2) CN103857397B (zh)
AU (1) AU2012308274B2 (zh)
BR (1) BR112014005064A2 (zh)
CA (1) CA2845007C (zh)
CL (1) CL2014000506A1 (zh)
CO (1) CO6970589A2 (zh)
HK (1) HK1199840A1 (zh)
IL (1) IL230940B (zh)
MX (1) MX2014001933A (zh)
PE (1) PE20142353A1 (zh)
RU (1) RU2014105881A (zh)
SG (1) SG2014011811A (zh)
TW (2) TWI588145B (zh)
WO (1) WO2013040471A2 (zh)
ZA (1) ZA201401268B (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765737B1 (en) * 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9394294B2 (en) * 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9358237B2 (en) 2010-07-23 2016-06-07 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
US9040520B2 (en) 2011-09-15 2015-05-26 Demerx, Inc. Noribogaine salt ansolvates
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
HUE035069T2 (en) 2011-12-28 2018-05-02 Global Blood Therapeutics Inc Substituted benzaldehyde compounds and their use to increase tissue oxygenation
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
JP2016508979A (ja) 2012-12-20 2016-03-24 デメレックス， インコーポレイテッド 置換ノルイボガイン
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014143201A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
KR20150132146A (ko) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2903022C (en) 2013-03-15 2021-11-09 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
JP6809681B2 (ja) 2014-02-07 2021-01-06 グローバル ブラッド セラピューティクス インコーポレイテッド ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
AU2014383143A1 (en) 2014-02-18 2016-09-29 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9345711B2 (en) 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
PT3223906T (pt) 2014-11-26 2021-05-05 Demerx Inc Métodos e composições para potencializar a ação de analgésicos de opioides usando alcaloides de iboga
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin
WO2023150547A2 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. Psychedelic compounds and their therapeutic uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2813873A (en) * 1957-11-19 Derivatives of the ibogaine alkaloids
GB789870A (en) * 1955-10-10 1958-01-29 Gobey Lab Alkaloid derivatives
MX9701430A (es) * 1994-07-25 1997-12-31 Nda Int Inc Un metodo de tratamiento de dependencia quimica en mamiferos y una composicion para el mismo.
US5591738A (en) * 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
EP2246058A1 (en) 1997-09-04 2010-11-03 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
RU2005117630A (ru) * 2002-11-08 2006-01-20 Дов Фармасьютикал, Инк. (Us) Полиморфы гидрохлорида бицифадина
AU2007209992A1 (en) * 2006-01-31 2007-08-09 Thallion Pharmaceuticals Inc. Crystalline forms of a farnesyl dibenzodiazepinone
US9358237B2 (en) * 2010-07-23 2016-06-07 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) * 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9040520B2 (en) 2011-09-15 2015-05-26 Demerx, Inc. Noribogaine salt ansolvates

Also Published As

Publication number Publication date
TWI588145B (zh) 2017-06-21
IL230940B (en) 2022-04-01
CA2845007C (en) 2020-09-29
US9617265B2 (en) 2017-04-11
KR20200115661A (ko) 2020-10-07
KR20140062472A (ko) 2014-05-23
MX2014001933A (es) 2014-03-27
WO2013040471A3 (en) 2013-05-10
US20160108043A1 (en) 2016-04-21
RU2014105881A (ru) 2015-10-20
IL230940A0 (en) 2014-03-31
NZ620948A (en) 2016-10-28
US20130072472A1 (en) 2013-03-21
US20170022194A1 (en) 2017-01-26
CN105949193A (zh) 2016-09-21
KR102381792B1 (ko) 2022-04-01
US9040520B2 (en) 2015-05-26
EP2755658A4 (en) 2015-03-18
CO6970589A2 (es) 2014-06-13
SG2014011811A (en) 2014-05-29
CN103857397B (zh) 2016-08-17
PE20142353A1 (es) 2015-01-10
WO2013040471A2 (en) 2013-03-21
TW201313720A (zh) 2013-04-01
EP2755658A2 (en) 2014-07-23
US20170022193A1 (en) 2017-01-26
CN103857397A (zh) 2014-06-11
ZA201401268B (en) 2016-11-30
CA2845007A1 (en) 2013-03-21
TW201726676A (zh) 2017-08-01
AU2012308274B2 (en) 2017-08-17
AU2012308274A1 (en) 2014-02-27
BR112014005064A2 (pt) 2017-04-04
CL2014000506A1 (es) 2014-08-22

Similar Documents

Publication Publication Date Title
HK1199840A1 (zh) 降伊波加因碱鹽非溶劑化物
HK1203196A1 (zh) 取代的苄基吡唑
DK3798230T3 (en) Terapeutiske antistoffer
EP2790561A4 (en) DISHWASHER
EP2755962A4 (en) AZAINDAZOLES
EP2715659A4 (en) ABOUT FEED
HK1188451A1 (zh) 咪唑並噁嗪化合物或其鹽
EP2754063A4 (en) EXTENSIBILITY OF THE SMB2 PROTOCOL
EP2723631A4 (en) QUADFOILER
GB201304499D0 (en) Carcainium Salts
EP2776444A4 (en) dihydropteridinones
AP2014007621A0 (en) 2-Thiopyrimidinones
EP2695208A4 (en) MICRO-THERMOCOUPLE
HUE036428T2 (hu) Sóhelyettesítõ
EP2679138A4 (en) Borescope
EP2708561A4 (en) BIO-PIN
EP2785766A4 (en) HYDROXYPOLYAMINSALZE
HK1215571A1 (zh) 二鹽酸科比思特
DK2770906T3 (en) Applanationstonometer
EP2684382A4 (en) EARPHONES
EP2698098A4 (en) campimeter
EP2716258A4 (en) INTRASTOMAL SEGMENT
EP2694655A4 (en) pavec
EP2702929A4 (en) campimeter
GB201100001D0 (en) TidySqueeze2